The Dr. Makis Cancer Protocol Handbook

This is a structured educational overview of a widely discussed topic in modern health conversations. It focuses on the increasing interest in repurposed drugs—particularly ivermectin, a well-established antiparasitic medication for humans, and fenbendazole, a veterinary antiparasitic agent—in relation to complementary and experimental cancer care discussions. While these compounds have known uses in parasitic infections, their application in oncology remains unproven and is not part of standard, evidence-based medical practice. This handbook aims to organize the available information, theories, and public claims in a clear and balanced way for critical understanding.

Cancer is a complex group of diseases characterized by uncontrolled cell growth driven by genetic mutations, cellular dysfunction, and interactions with the immune system and environment. Modern oncology relies on treatments that have undergone extensive clinical testing, including chemotherapy, radiation therapy, surgery, immunotherapy, and targeted drug therapies. These treatments are supported by rigorous scientific evidence and regulatory approval processes designed to ensure safety and effectiveness. In contrast, repurposed drug concepts like those discussed in the Makis Protocol remain largely in the realm of theoretical exploration, preclinical studies, and anecdotal reports rather than validated clinical oncology practice.

The “Makis Protocol,” as referenced in online discussions, is not an officially recognized medical guideline or standardized treatment framework. Instead, it is a loosely defined concept that has circulated in alternative health communities, often combining interpretations of existing research with off-label speculation. It is commonly associated with ivermectin and fenbendazole, two drugs that have attracted attention due to laboratory observations suggesting possible interactions with cellular pathways. However, these findings are preliminary and have not been confirmed through large-scale human clinical trials for cancer treatment.

Ivermectin is an approved antiparasitic drug widely used in human medicine for conditions such as parasitic worm infections and scabies. Fenbendazole, on the other hand, is primarily used in veterinary medicine and has not been approved as a cancer treatment for humans. Interest in these compounds has grown due to hypotheses about their potential effects on cellular processes such as microtubule function, immune modulation, and cancer cell signaling. However, these mechanisms remain theoretical in the context of human oncology and require far more rigorous investigation.

This handbook also explores how such protocols are described, including discussions around usage patterns, combinations, and dosing concepts found in informal or online sources. It is important to understand that no standardized or clinically validated dosing guidelines exist for these compounds in cancer treatment, and any such references should be treated strictly as informational rather than medical recommendations.

A key focus of this guide is to help readers distinguish between established medical science and emerging or speculative ideas. While drug repurposing is a legitimate area of scientific research, it requires careful validation through controlled clinical studies before it can be considered safe or effective. Misinterpretation of early-stage research can lead to confusion, particularly in sensitive areas such as cancer care.